Core Viewpoint - The company aims to mitigate foreign exchange risk and enhance the efficiency of foreign currency fund usage by engaging in foreign exchange derivative trading with a limit not exceeding 500 million RMB or its equivalent in foreign currency [1] Group 1: Foreign Exchange Derivative Trading - The company and its subsidiaries plan to conduct foreign exchange derivative trading within a limit of 500 million RMB or equivalent foreign currency [1] - The trading period is set for 12 months from the date of board approval, with the limit being available for rolling use [1] - The maximum amount for margin and premium is expected to be 50 million RMB, funded through self-owned or self-raised capital [1] Group 2: Risk Management and Compliance - The company has established a system to control risks associated with the trading activities [1] - The accounting treatment will be conducted in accordance with accounting standards [1] - The board of directors has approved the proposal, and it does not require submission to the shareholders' meeting [1]

Group 1 - The core viewpoint of the article highlights that Weili Medical (603309) has seen a stock price increase of 4.18%, closing at 14.94 yuan as of February 6, 2026, compared to 14.34 yuan the previous week [1] - The company achieved a total market capitalization of 4.361 billion yuan, ranking 88th out of 129 in the medical device sector and 3870th out of 5186 in the A-share market [1] - The highest intraday price recorded for Weili Medical during the week was 14.99 yuan, while the lowest was 13.85 yuan [1] Group 2 - Weili Medical announced that multiple products have received EU MDR certification, allowing them to be sold in the European market [1] - The certified products include a range of medical devices such as urinary catheter care kits, drainage bags, puncture guides, and various types of catheters and tubes [1] - The certification was issued by TÜV SÜD Product Service GmbH, with a validity period until May 15, 2028, or December 5, 2028, confirming compliance with the latest EU medical device regulations [1]

Core Viewpoint - The company, Shanwaishan, has shown significant growth in its blood purification equipment and consumables sales, indicating a strong market position and potential for future expansion in both domestic and international markets. Group 1: Financial Performance - In Q3 2025, the revenue from blood purification equipment reached 393.08 million yuan, representing a year-on-year growth of 39.70% [7] - During the same period, revenue from blood purification consumables was 136.96 million yuan, with a year-on-year increase of 46.47% [7] - The total market capitalization of Shanwaishan is currently 5.456 billion yuan, ranking 68th in the medical device sector [1] Group 2: Market Position and Strategy - The company holds a leading position in the domestic market, with a market share of 21.44% for blood dialysis machines, making it the top domestic brand [3] - The market share for continuous blood purification equipment is 20.77%, also leading the industry [3] - The company is focusing on technological innovation and market demand to drive growth, aiming to expand both domestically and internationally [3] Group 3: International Expansion - The company has made strides in its international strategy, achieving breakthroughs in emerging markets such as Latin America and Africa, with 22 new overseas device registrations [4] - In Q3 2025, revenue from international markets reached 131.92 million yuan, reflecting a year-on-year growth of 43.04% [4] Group 4: Policy and Market Opportunities - The National Development and Reform Commission has proposed policies to enhance the efficiency of equipment update loans, which the company is actively following to explore new opportunities [2] - The company is closely monitoring the price trends and rhythm of centralized procurement for consumables, indicating a proactive approach to market changes [3] Group 5: Future Plans - The company is progressing with its fundraising projects and will continue to monitor market dynamics to ensure successful implementation [5] - Future stock incentive plans will be evaluated based on operational performance, with timely disclosures as necessary [6]

Core Viewpoint - Gongdong Medical (605369) has shown a price increase of 3.17% this week, closing at 19.51 yuan, with a total market capitalization of 4.302 billion yuan [1] Company Announcements - Gongdong Medical's testing center has received accreditation from the China National Accreditation Service for Conformity Assessment (CNAS), with a registration number CNAS L25064, valid until January 18, 2032 [1] - The accreditation indicates that the testing center meets the ISO/IEC 17025:2017 standards, enhancing its testing capabilities and gaining national and international recognition [1] - This recognition will help reduce market entry barriers and testing costs for products, improve quality control and R&D capabilities, and increase customer trust, although it is not expected to have a significant impact on the company's operating performance [1]

Core Viewpoint - As of February 6, 2026, Jiet Bio (688026) has seen a stock price increase of 2.56% from the previous week, closing at 18.4 yuan, with a total market capitalization of 2.583 billion yuan [1] Group 1: Company Stock Performance - Jiet Bio's stock reached a weekly high of 18.68 yuan and a low of 17.77 yuan during the week [1] - The company ranks 123rd out of 129 in the medical device sector and 4926th out of 5186 in the overall A-share market by market capitalization [1] Group 2: Share Buyback Announcement - The company announced a share buyback plan with a total fund of no less than 15 million yuan and no more than 30 million yuan, with a maximum buyback price of 25.32 yuan per share [1] - As of January 31, 2026, Jiet Bio has repurchased 272,799 shares, accounting for 0.19% of the total share capital, at an average price between 18.05 yuan and 18.43 yuan, totaling 4.9714 million yuan spent [1][3] Group 3: Legal Matters - Jiet Bio is involved in a lawsuit against Shenzhen Hesheng Medical Technology Co., regarding a contract dispute with a claim amount of 10,340,829 yuan [2] - The court ruled to terminate the contract and dismissed other claims, with the company fully provisioning for the prepaid amount as bad debt [2][3]

Core Viewpoint - Xiangsheng Medical (688358) experienced a decline in stock price, closing at 35.71 yuan, down 2.48% from the previous week, indicating market volatility and investor sentiment [1] Company Announcements - Xiangsheng Medical announced a cash dividend of 0.30 yuan per share (before tax), with a total distribution amounting to 33,637,683.90 yuan based on a total share capital of 112,125,613 shares [1] - The record date for the dividend distribution is set for February 11, 2026, with the ex-dividend date on February 12, 2026, and the payment date also on February 12, 2026 [1] - The profit distribution will not include stock dividends or capital increases, and the tax on dividend income will be executed according to the nature of the shareholders [1]

Core Viewpoint - The company, Xinmai Medical, has seen a stock price increase of 3.1% this week, closing at 97.98 yuan, with a total market capitalization of 12.077 billion yuan, ranking 27th in the medical device sector and 1716th in the A-share market [1] Company Announcements - Xinmai Medical's wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate for polyvinyl alcohol embolization microspheres, intended for the treatment of hypervascular solid organ malignant tumors [1] - This product marks the company's first embolization product in the field of tumor interventional therapy, with the registration certificate valid from January 28, 2026, to January 27, 2031 [1] - The company has multiple other tumor interventional products that have been approved or are under research, but actual sales will depend on market promotion efforts, making future revenue impact unpredictable [1]

Core Viewpoint - Zhendemedical (603301) has seen a price increase of 6.66% this week, closing at 73.35 yuan as of February 6, 2026, with a total market capitalization of 19.499 billion yuan [1] Company Announcements - Zhendemedical announced a change in the project quality reviewer, with Wang Wen taking over from Zheng Chuanxian due to work adjustments [1] - Wang Wen has been a certified public accountant since 2011 and has been providing audit services to the company since 2025, ensuring independence and no penalties for professional conduct [1] - The change in the quality reviewer will not affect the normal conduct of the company's 2025 financial statement and internal control audit [1]

Core Viewpoint - Xinhua Medical (600587) experienced a slight decline in stock price, closing at 15.38 yuan on February 6, 2026, with a trading volume of 91,200 hands and a turnover of 141 million yuan [1]. Group 1: Stock Performance and Fund Flow - On February 6, 2026, the main funds saw a net outflow of 8.22 million yuan, accounting for 5.82% of the total turnover, while retail investors had a net inflow of 2.90 million yuan, representing 2.05% of the total turnover [1]. - Over the past five days, the stock price fluctuated, with a closing price of 15.38 yuan on February 6, reflecting a decrease of 0.45% [2]. - The five-day fund flow data indicates varying trends, with significant net inflows and outflows from different investor categories [2]. Group 2: Company Financials and Industry Comparison - Xinhua Medical's total market capitalization is 9.33 billion yuan, which is below the industry average of 11.09 billion yuan, ranking 43rd out of 128 companies in the medical device sector [3]. - The company reported a net profit of 434 million yuan for the first three quarters of 2025, a decrease of 29.61% year-on-year, with a gross margin of 25.11%, significantly lower than the industry average of 50.55% [3]. - The company's return on equity (ROE) stands at 5.65%, which is relatively strong compared to the industry average of 0.42%, ranking 48th in the sector [3]. Group 3: Analyst Ratings - In the last 90 days, two institutions have given a rating of "buy" for Xinhua Medical, with a target price averaging 20.0 yuan [4].

Core Viewpoint - The event "Guanghuo Xing Tianxia: Zhongshan Department Store Enters Shenzhen" aims to promote integration and collaboration between Zhongshan and Shenzhen, showcasing Zhongshan's products and culture to Shenzhen residents [1][3]. Group 1: Event Overview - The event was launched on February 7, supported by various government departments and aimed at enhancing the integration of Zhongshan and Shenzhen [1]. - The event features over 2,000 square meters of exhibition space with seven themed areas, showcasing more than 260 companies and their products [6]. Group 2: Government and Leadership Involvement - Zhongshan's leadership emphasized the importance of this event in promoting local products and fostering a sense of community between the two cities [3]. - Officials from both cities participated in the event, highlighting the collaborative efforts to enhance economic ties and consumer engagement [5][8]. Group 3: Product and Industry Highlights - The "Intelligent Manufacturing Zhongshan" section attracted over 150 manufacturing companies, presenting more than 400 products in fields such as robotics and medical devices [6]. - A variety of local agricultural products were showcased, including over 100 items from Zhongshan's agricultural sector [6]. Group 4: Economic Impact - The event facilitated 36 contracts between enterprises from both cities, with a total value of 3 billion yuan [8].